Holen Sie sich die Stockscreener-App
4.54
6.82%
0.29
Handel nachbörslich:
4.45
-0.09
-1.98%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences (SLDB) Maintains Market Outperform Rating | SLDB Stock News - GuruFocus
Transcript : Solid Biosciences Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Solid Biosciences (SLDB) Announces Stock Grants Under Inducement Plan | SLDB Stock News - GuruFocus
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Awards Strategic RSU Grants: New Hires Receive 34,550 Shares Under Nasdaq Compensation Rule - Stock Titan
Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Northern Trust Corp Has $676,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Reports Increased Loss Amid R&D Expansion - TipRanks
BNP Paribas Financial Markets Acquires New Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
D. E. Shaw & Co. Inc. Buys Shares of 51,972 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough - Investing.com Nigeria
Research Analysts Set Expectations for SLDB FY2025 Earnings - Defense World
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fi - GuruFocus
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fitzgerald | SLDB Stock News - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given New $15.00 Price Target at Chardan Capital - Defense World
Solid Biosciences (SLDB) Maintains Buy Rating Amid Revised Price Target | SLDB Stock News - GuruFocus
Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating - marketscreener.com
Q1 Earnings Forecast for SLDB Issued By William Blair - Defense World
Wedbush Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance
Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus
SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus
Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com
Solid Biosciences (SLDB) Target Price Updated by Wedbush Analyst - GuruFocus
Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus
Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks
Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus
Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com
Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks
SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus
Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Form 424B5 Solid Biosciences Inc. - StreetInsider
Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | SLDB Stock News - GuruFocus
Solid Biosciences Provides Business Update and Financial Results for Q1 2025, Advances Gene Therapy Programs for Duchenne Muscular Dystrophy, Friedreich's Ataxia, and CPVT - Nasdaq
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Solid Biosciences Reports Breakthrough in Duchenne Treatment: Q1 Results Reveal Strong Pipeline Progress - Stock Titan
Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday - Defense World
Partner With Us - Solid Biosciences
Solid Biosciences Reports Quarterly Loss Per Share Of $0.54 - Reuters
Analysts Have Conflicting Sentiments on These Healthcare Companies: Axsome Therapeutics (AXSM), Premier (PINC) and Solid Biosciences (SLDB) - The Globe and Mail
Solve FSHD supports Armatus Bio drug for facioscapulohumeral muscular dystrophy - BioWorld MedTech
Invesco Ltd. Invests $49,000 in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan
Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times
Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times
Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):